Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Other Non-Current Liabilities (2017 - 2025)

Autolus Therapeutics' Other Non-Current Liabilities history spans 7 years, with the latest figure at $477000.0 for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities rose 11.97% year-over-year to $477000.0; the TTM value through Dec 2025 reached $477000.0, up 11.97%, while the annual FY2025 figure was $477000.0, 11.97% up from the prior year.
  • Other Non-Current Liabilities reached $477000.0 in Q4 2025 per AUTL's latest filing, up from $472000.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $477000.0 in Q2 2025 to a low of $105000.0 in Q3 2022.
  • Average Other Non-Current Liabilities over 5 years is $296647.1, with a median of $357000.0 recorded in 2023.
  • Peak YoY movement for Other Non-Current Liabilities: dropped 9.38% in 2022, then soared 258.77% in 2024.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $128000.0 in 2021, then decreased by 9.38% to $116000.0 in 2022, then skyrocketed by 207.76% to $357000.0 in 2023, then increased by 19.33% to $426000.0 in 2024, then rose by 11.97% to $477000.0 in 2025.
  • Per Business Quant, the three most recent readings for AUTL's Other Non-Current Liabilities are $477000.0 (Q4 2025), $472000.0 (Q3 2025), and $477000.0 (Q2 2025).